Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly

Abstract

Etoricoxib is a selective cyclooxygenase-2 inhibitor, with a lower risk of gastrointestinal toxicity compared to traditional nonsteroidal anti-inflammatory drugs (NSAIDs). We evaluated the effectiveness and tolerability of etoricoxib in extremely elderly patients with chronic pain due to osteoarthritis (OA). A prospective, single-center, single-arm study was conducted, enrolling 19 extremely elderly men with OA (mean age 85.9, range 79-96 years), who responded inadequately to NSAIDs or other analgesics. Patients were switched to etoricoxib, 60 mg once daily for 4 weeks, without prior medication washout. Data were recorded before and after etoricoxib treatment. The primary endpoint was improvement in pain, assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) after the 4-week treatment. Other endpoints included the Brief Pain Inventory Short Form (BPI-SF), Treatment Satisfaction Questionnaire for Medication (TSQM), Short Form 36 (SF36), and European Quality of Life-5 Dimensions (EQ-5D). Safety and tolerability were assessed by collecting adverse events data. Pain and disability scores measured by WOMAC index were lower after treatment (pain, p ≤ 0.001; disability, p = 0.020). BPI-SF showed a significant improvement in joint function when walking and performing normal work (walking, p = 0.021; normal work, p = 0.030). SF36 scores improved for 7 out of 11 items after etoricoxib treatment (#1, p = 0.032; #4, p = 0.026; #5, p = 0.017; #6, p = 0.008; #7, p = 0.009; #8, p = 0.013; and #10, p = 0.038). EQ-5D showed a significant improvement in visual analogue scale scores (p = 0.036). TSQM results demonstrated a higher patient perception of overall satisfaction. No adverse events were reported. Pain relief, joint function, quality of life, and treatment satisfaction improved significantly in elderly patients with OA after etoricoxib administration.

Does low dose of etoricoxib play pre-emptive analgesic effect in third molar surgery? A randomized clinical trial

“…Disability and pain interference in daily activities were significantly improved [ 23 ]. In addition, the pain and disability scores measured by the Western Ontario and McMaster’s University OA index (WOMAC) in 19 extremely elderly men with OA (mean age, 85.9 years; age range, 79–96 years) were lower after treatment with 60 mg of etoricoxib once daily for 4 weeks; no adverse events were also reported [ 24 ]. A double-blind and placebo-controlled study conducted a two-part dose-ranging clinical trial of etoricoxib (5–90 mg/day) starting at 14-week; during which, 60 mg of etoricoxib was found to have the best analgesic effect according to the WOMAC pain scale [ 25 ].…”

Treatment satisfaction in atopic dermatitis relates to patient‐reported severity: A cross‐sectional study

“…The TSQM‐9 focuses specifically on the three domains of Effectiveness, Convenience, and Global Satisfaction . The TSQM‐9 has been used to assess treatment satisfaction for some diseases but has not yet been applied to atopic dermatitis.…”

Etoricoxib in the treatment of osteoarthritis

“…В небольшом (n = 19) проспективном исследовании Wen-Nan Huang и соавт. [32] при назначении эторикоксиба на протяжении 4 недель лицам в возрасте 75 лет и старше (max возраст -96 лет) с высокой степенью коморбидности при предшествующей неэффективности других НПВП отмечалось значимое уменьшение показателей WOMAC: боли, скованности и функциональной недостаточности. В среднем боль уменьшилась с 18 баллов до 4 (р<0,001), скованность -с 4 до 2 (р<0,02) и степень функциональной недостаточности -с 80,5 до 38,5 (р<0,001).…”